News
NEW YORK--(BUSINESS WIRE)-- Pfizer Inc. (NYSE: PFE) today announced the decision to discontinue development of danuglipron (PF-06882961), an oral glucagon-like peptide-1 (GLP-1) receptor agonist ...
Reserve your free spot now. Pfizer Inc. PFE is discontinuing development of an oral glucagon-like peptide-1 (GLP-1) receptor agonist being investigated for chronic weight management. Pfizer’s ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback